melatonin has been researched along with Metastase in 53 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent observations have shown that the pineal hormone melatonin (MLT) may modulate oestrogen receptor (ER) expression and inhibit breast cancer cell growth." | 9.08 | Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. ( Barni, S; Cazzaniga, M; Esposti, D; Fossati, V; Lissoni, P; Meregalli, S; Tancini, G, 1995) |
| "This review article discusses recent work on the melatonin-mediated circadian regulation and integration of molecular, dietary, and metabolic signaling mechanisms involved in human breast cancer growth and the consequences of circadian disruption by exposure to light at night (LAN)." | 8.87 | Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. ( Blask, DE; Dauchy, E; Dauchy, RT; Duplessis, T; Hill, SM; Mao, L; Sauer, LA; Xiang, S; Yuan, L, 2011) |
| "Melatonin exerts oncostatic effects on breast cancer via immunomodulation and antioxidation." | 8.12 | Effects of Melatonin and Doxorubicin on Primary Tumor And Metastasis in Breast Cancer Model. ( Aytac, G; Dilmac, S; Farooqi, AA; Sindel, M; Tanriover, G, 2022) |
| "MTT, wound healing, transwell assay and western blotting were conducted to determine the effect of melatonin on osteosarcoma cell invasion and migration and downregulation of SOX9-mediated signaling." | 7.88 | Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling. ( Fu, Q; He, J; Lai, L; Lian, W; Lin, N; Qu, H; Wang, C; Wang, Q; Xue, Y; Ye, Z; Zhong, L, 2018) |
| "Melatonin inhibition of Rsk2 represses the metastatic phenotype in breast cancer cells suppressing EMT or inhibiting other mechanisms that promote metastasis; disruption of the melatonin signal may promote metastatic progression in breast cancer." | 7.83 | Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression. ( Blask, DE; Dauchy, RT; Frasch, T; Hill, SM; Mao, L; Pointer, D; Reynolds, A; Summers, W; Wren-Dail, MA; Xiang, S; Yuan, L, 2016) |
| "Daytime plasma melatonin values were measured by radioimmune assay in 86 patients with breast cancer; 280 assays were done and compared with the clinical status of the patients." | 7.68 | Plasma melatonin in patients with breast cancer. ( Falkson, G; Falkson, HC; Meyer, BJ; Rapoport, BL; Steyn, ME, 1990) |
| "Since there is no effective second line chemotherapy in colorectal cancer resistant to fluorouracil, this study was carried out to evaluate the therapeutic activity of the pineal hormone melatonin, which has appeared to have antineoplastic activity in some experimental conditions, in patients with metastatic colorectal carcinoma who did not respond to fluorouracil." | 7.68 | A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1990) |
| "Melatonin is an endogenous hormone primarily known for its action on the circadian rhythms." | 6.58 | Therapeutic potential of melatonin for breast cancer radiation therapy patients. ( Griffin, F; Marignol, L, 2018) |
| "5-MTP blocks cancer cell migration and invasion in vitro and inhibits tumor growth and cancer metastasis in a xenograft model." | 6.50 | 5-methoxyindole metabolites of L-tryptophan: control of COX-2 expression, inflammation and tumorigenesis. ( Chang, TC; Cheng, HH; Wu, KK, 2014) |
| "Breast cancer is the most common neoplastic disorder diagnosed in women." | 5.51 | Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway. ( El-Sokkary, GH; Ismail, IA; Saber, SH, 2019) |
| "Melatonin and Y27632 treatments reduced cell viability and invasion/migration of both cell lines and decreased ROCK-1 gene expression in metastatic cells and protein expression in nonmetastatic cell line." | 5.43 | Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. ( Arbab, AS; Borin, TF; Coimbra, VB; de Oliveira, JG; Fabri, VA; Ferreira, LC; Gelaleti, GB; Iskander, AS; Jardim-Perassi, BV; Moschetta, MG; Shankar, A; Varma, NR; Zuccari, DA, 2016) |
| "Three types of human breast cancer cells were used in this study: MDA-MB-435, MDA-MB-231, and MCF-7." | 5.31 | Studies of the interactions between melatonin and 2 Hz, 0.3 mT PEMF on the proliferation and invasion of human breast cancer cells. ( Anderson, KW; Leman, ES; Sisken, BF; Zimmer, S, 2001) |
| "Melatonin was also able to block 17beta-estradiol-induced invasion (P < 0." | 5.30 | Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. ( Cos, S; Fernández, R; Güézmes, A; Sánchez-Barceló, EJ, 1998) |
| "Experimental studies have showed that hepatocellular carcinoma (HCC) cells are susceptible to cytolysis of interleukin (IL)-2-activated lymphocytes." | 5.29 | Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Conti, A; Lissoni, P; Maestroni, GJ; Piperno, A; Pozzi, M; Ricci, G; Tancini, G, 1994) |
| "Recent observations have shown that the pineal hormone melatonin (MLT) may modulate oestrogen receptor (ER) expression and inhibit breast cancer cell growth." | 5.08 | Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. ( Barni, S; Cazzaniga, M; Esposti, D; Fossati, V; Lissoni, P; Meregalli, S; Tancini, G, 1995) |
| "This review article discusses recent work on the melatonin-mediated circadian regulation and integration of molecular, dietary, and metabolic signaling mechanisms involved in human breast cancer growth and the consequences of circadian disruption by exposure to light at night (LAN)." | 4.87 | Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. ( Blask, DE; Dauchy, E; Dauchy, RT; Duplessis, T; Hill, SM; Mao, L; Sauer, LA; Xiang, S; Yuan, L, 2011) |
| "Melatonin exerts oncostatic effects on breast cancer via immunomodulation and antioxidation." | 4.12 | Effects of Melatonin and Doxorubicin on Primary Tumor And Metastasis in Breast Cancer Model. ( Aytac, G; Dilmac, S; Farooqi, AA; Sindel, M; Tanriover, G, 2022) |
| "MTT, wound healing, transwell assay and western blotting were conducted to determine the effect of melatonin on osteosarcoma cell invasion and migration and downregulation of SOX9-mediated signaling." | 3.88 | Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling. ( Fu, Q; He, J; Lai, L; Lian, W; Lin, N; Qu, H; Wang, C; Wang, Q; Xue, Y; Ye, Z; Zhong, L, 2018) |
| "Melatonin inhibition of Rsk2 represses the metastatic phenotype in breast cancer cells suppressing EMT or inhibiting other mechanisms that promote metastasis; disruption of the melatonin signal may promote metastatic progression in breast cancer." | 3.83 | Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression. ( Blask, DE; Dauchy, RT; Frasch, T; Hill, SM; Mao, L; Pointer, D; Reynolds, A; Summers, W; Wren-Dail, MA; Xiang, S; Yuan, L, 2016) |
| "Daytime plasma melatonin values were measured by radioimmune assay in 86 patients with breast cancer; 280 assays were done and compared with the clinical status of the patients." | 3.68 | Plasma melatonin in patients with breast cancer. ( Falkson, G; Falkson, HC; Meyer, BJ; Rapoport, BL; Steyn, ME, 1990) |
| "Since there is no effective second line chemotherapy in colorectal cancer resistant to fluorouracil, this study was carried out to evaluate the therapeutic activity of the pineal hormone melatonin, which has appeared to have antineoplastic activity in some experimental conditions, in patients with metastatic colorectal carcinoma who did not respond to fluorouracil." | 3.68 | A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1990) |
| "In order to investigate the pineal function and its relation with the hypophysis in human neoplasms, melatonin and GH serum levels were determined in 63 patients, 42 affected by solid tumours and 21 by lymphoma or leukaemia." | 3.67 | The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. ( Bajetta, E; Bastone, A; di Bella, L; Esposti, D; Esposti, G; Lissoni, P; Mauri, R; Rovelli, F; Sala, R; Viviani, S, 1987) |
| "Melatonin is a pleotropic molecule with numerous biological activities." | 2.72 | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities. ( Abuawad, A; Alsayed, AR; Daoud, S; Mahmod, AI; Talib, WH, 2021) |
| "This study shows that cancer neuroimmunotherapy with low-dose IL-2 and the pineal hormone melatonin may prolong survival time and improve the quality of life of patients with metastatic solid tumours who do not respond to conventional therapies." | 2.68 | A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. ( Ardizzoia, A; Barni, S; Cazzaniga, M; Fossati, V; Frigerio, F; Lissoni, P; Tancini, G, 1995) |
| "Melatonin is an indole produced by the pineal gland at night under normal light or dark conditions, and its levels, which are higher in children than in adults, begin to decrease prior to the onset of puberty and continue to decline thereafter." | 2.66 | New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence. ( Hsieh, YH; Lin, CW; Lu, KH; Reiter, RJ; Su, SC; Yang, SF, 2020) |
| "Melatonin is an endogenous hormone primarily known for its action on the circadian rhythms." | 2.58 | Therapeutic potential of melatonin for breast cancer radiation therapy patients. ( Griffin, F; Marignol, L, 2018) |
| "While the emphasis of melatonin/cancer research has been on the role of the indoleamine in restraining breast cancer, this is changing quickly with many cancer types having been shown to be susceptible to inhibition by melatonin." | 2.55 | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. ( Acuna-Castroviejo, D; Qin, L; Reiter, RJ; Rosales-Corral, SA; Tan, DX; Xu, K; Yang, SF, 2017) |
| "Melatonin is a pleiotropic anti-cancer molecule that affects malignant cells via multiple mechanisms." | 2.55 | Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer. ( Abdollahi, M; Asghari, MH; Fallah, M; Ghobadi, E; Moloudizargari, M, 2017) |
| "Melatonin is a naturally occurring molecule secreted by the pineal gland and known as a gatekeeper of circadian clocks." | 2.55 | Cancer metastasis: Mechanisms of inhibition by melatonin. ( Chung, WH; Hsieh, MJ; Reiter, RJ; Su, SC; Yang, SF; Yang, WE, 2017) |
| "5-MTP blocks cancer cell migration and invasion in vitro and inhibits tumor growth and cancer metastasis in a xenograft model." | 2.50 | 5-methoxyindole metabolites of L-tryptophan: control of COX-2 expression, inflammation and tumorigenesis. ( Chang, TC; Cheng, HH; Wu, KK, 2014) |
| "Sirtuins, enzymes involved in metastasis formation, have also been detected." | 1.72 | The role of selected molecular factors in ovarian cancer metastasis. ( Fechner, J; Markowska, A; Markowska, J; Sawicki, W; Zurawski, J, 2022) |
| "Melatonin was administrated either before or after the injection of 4TLM cells into the mammary pad." | 1.62 | Melatonin decreases metastasis, primary tumor growth and angiogenesis in a mice model of breast cancer. ( Aytac, G; Dilmac, S; Karadas, AK; Tanriover, G, 2021) |
| "Head and neck squamous cell carcinoma (HNSCC) cells with or without melatonin treatment were used as a research platform." | 1.62 | FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis. ( Jensen, C; Lang, L; Loveless, R; Prieto-Dominguez, N; Shay, C; Teng, Y; Xiong, Y, 2021) |
| "Melatonin has shown anticancer activity in experimental investigations." | 1.62 | Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression. ( Chang, AC; Chen, PC; Chen, SS; Chen, YH; Lai, YW; Lin, LW; Lin, TH; Tai, HC; Tang, CH; Wang, PC; Wang, SW, 2021) |
| "Remarkably, acidosis-mediated metastasis was significantly alleviated by BMAL1 overexpression in breast cancer cells." | 1.56 | Extracellular Acidosis Promotes Metastatic Potency via Decrease of the ( Kim, K; Kim, SK; Kwon, SH; Kwon, YJ; Lee, SH; Park, IC; Park, JW; Park, S; Park, SK; Seo, EB; Ye, SK, 2020) |
| "Breast cancer is the most common neoplastic disorder diagnosed in women." | 1.51 | Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway. ( El-Sokkary, GH; Ismail, IA; Saber, SH, 2019) |
| "Melatonin and Y27632 treatments reduced cell viability and invasion/migration of both cell lines and decreased ROCK-1 gene expression in metastatic cells and protein expression in nonmetastatic cell line." | 1.43 | Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. ( Arbab, AS; Borin, TF; Coimbra, VB; de Oliveira, JG; Fabri, VA; Ferreira, LC; Gelaleti, GB; Iskander, AS; Jardim-Perassi, BV; Moschetta, MG; Shankar, A; Varma, NR; Zuccari, DA, 2016) |
| "Melatonin IR was found in all SI-NETS." | 1.43 | Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours. ( Ali, A; Cunningham, JL; Janson, ET; Rasmusson, AJ; Söderquist, F; Stridsberg, M, 2016) |
| "Treatment with melatonin did not demonstrate inhibition of the expression of genes HIF-1α, VEGF and ROCK-1 in line SCC25, which has different molecular characteristics and greater degree of malignancy when compared to the line SCC9." | 1.40 | Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. ( Colombo, J; Goncalves, Ndo N; Jardim-Perassi, BV; Lopes, JR; Moschetta, MG; Rodrigues, RV; Zuccari, DA, 2014) |
| "Histopathology revealed no metastasis in the liver, small intestine and large intestine in any of the animals in the experimental groups; however this process was evident in the lungs and kidneys, being inhibited by melatonin administration." | 1.39 | Melatonin effect on the ultrastructure of Ehrlich ascites tumor cells, lifetime and histopathology in Swiss mice. ( Alves, LC; Batista, AP; da Silva, TG; de Medeiros, PL; dos Santos, FA; Teixeira, ÁA; Teixeira, VW, 2013) |
| "Three types of human breast cancer cells were used in this study: MDA-MB-435, MDA-MB-231, and MCF-7." | 1.31 | Studies of the interactions between melatonin and 2 Hz, 0.3 mT PEMF on the proliferation and invasion of human breast cancer cells. ( Anderson, KW; Leman, ES; Sisken, BF; Zimmer, S, 2001) |
| "Melatonin was also able to block 17beta-estradiol-induced invasion (P < 0." | 1.30 | Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. ( Cos, S; Fernández, R; Güézmes, A; Sánchez-Barceló, EJ, 1998) |
| "Experimental studies have showed that hepatocellular carcinoma (HCC) cells are susceptible to cytolysis of interleukin (IL)-2-activated lymphocytes." | 1.29 | Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Conti, A; Lissoni, P; Maestroni, GJ; Piperno, A; Pozzi, M; Ricci, G; Tancini, G, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (11.32) | 18.7374 |
| 1990's | 11 (20.75) | 18.2507 |
| 2000's | 4 (7.55) | 29.6817 |
| 2010's | 20 (37.74) | 24.3611 |
| 2020's | 12 (22.64) | 2.80 |
| Authors | Studies |
|---|---|
| Tanriover, G | 2 |
| Dilmac, S | 2 |
| Aytac, G | 2 |
| Farooqi, AA | 1 |
| Sindel, M | 1 |
| Diamantopoulou, Z | 1 |
| Castro-Giner, F | 1 |
| Schwab, FD | 1 |
| Foerster, C | 1 |
| Saini, M | 1 |
| Budinjas, S | 1 |
| Strittmatter, K | 1 |
| Krol, I | 1 |
| Seifert, B | 1 |
| Heinzelmann-Schwarz, V | 1 |
| Kurzeder, C | 1 |
| Rochlitz, C | 1 |
| Vetter, M | 1 |
| Weber, WP | 1 |
| Aceto, N | 1 |
| Markowska, A | 1 |
| Sawicki, W | 1 |
| Zurawski, J | 1 |
| Fechner, J | 1 |
| Markowska, J | 1 |
| Wu, H | 1 |
| Liu, J | 1 |
| Yin, Y | 1 |
| Zhang, D | 1 |
| Xia, P | 1 |
| Zhu, G | 1 |
| Lu, KH | 1 |
| Lin, CW | 2 |
| Hsieh, YH | 2 |
| Su, SC | 3 |
| Reiter, RJ | 4 |
| Yang, SF | 6 |
| Kwon, YJ | 1 |
| Seo, EB | 1 |
| Kwon, SH | 1 |
| Lee, SH | 1 |
| Kim, SK | 1 |
| Park, SK | 1 |
| Kim, K | 1 |
| Park, S | 1 |
| Park, IC | 1 |
| Park, JW | 1 |
| Ye, SK | 1 |
| Wen, YC | 1 |
| Lin, YW | 2 |
| Chu, CY | 2 |
| Yang, YC | 2 |
| Liu, YF | 1 |
| Hsiao, M | 2 |
| Lee, WJ | 2 |
| Chien, MH | 3 |
| Bu, S | 1 |
| Wang, Q | 2 |
| Sun, J | 1 |
| Li, X | 1 |
| Gu, T | 1 |
| Lai, D | 1 |
| Wang, SW | 1 |
| Tai, HC | 1 |
| Tang, CH | 1 |
| Lin, LW | 1 |
| Lin, TH | 1 |
| Chang, AC | 1 |
| Chen, PC | 1 |
| Chen, YH | 1 |
| Wang, PC | 1 |
| Lai, YW | 1 |
| Chen, SS | 1 |
| Banerjee, V | 1 |
| Sharda, N | 1 |
| Huse, J | 1 |
| Singh, D | 1 |
| Sokolov, D | 1 |
| Czinn, SJ | 1 |
| Blanchard, TG | 1 |
| Banerjee, A | 1 |
| Lang, L | 1 |
| Xiong, Y | 1 |
| Prieto-Dominguez, N | 1 |
| Loveless, R | 1 |
| Jensen, C | 1 |
| Shay, C | 1 |
| Teng, Y | 1 |
| Karadas, AK | 1 |
| Talib, WH | 1 |
| Alsayed, AR | 1 |
| Abuawad, A | 1 |
| Daoud, S | 1 |
| Mahmod, AI | 1 |
| Rosales-Corral, SA | 1 |
| Tan, DX | 1 |
| Acuna-Castroviejo, D | 1 |
| Qin, L | 1 |
| Xu, K | 1 |
| Picardo, M | 1 |
| Slominski, AT | 1 |
| Asghari, MH | 1 |
| Moloudizargari, M | 1 |
| Ghobadi, E | 1 |
| Fallah, M | 1 |
| Abdollahi, M | 1 |
| Griffin, F | 1 |
| Marignol, L | 1 |
| Qu, H | 1 |
| Xue, Y | 1 |
| Lian, W | 1 |
| Wang, C | 1 |
| He, J | 1 |
| Fu, Q | 1 |
| Zhong, L | 1 |
| Lin, N | 1 |
| Lai, L | 1 |
| Ye, Z | 1 |
| Bondy, SC | 1 |
| Campbell, A | 1 |
| El-Sokkary, GH | 1 |
| Ismail, IA | 1 |
| Saber, SH | 1 |
| Batista, AP | 1 |
| da Silva, TG | 1 |
| Teixeira, ÁA | 1 |
| de Medeiros, PL | 1 |
| Teixeira, VW | 1 |
| Alves, LC | 1 |
| dos Santos, FA | 1 |
| Wu, KK | 1 |
| Cheng, HH | 1 |
| Chang, TC | 1 |
| Goncalves, Ndo N | 1 |
| Rodrigues, RV | 1 |
| Jardim-Perassi, BV | 2 |
| Moschetta, MG | 2 |
| Lopes, JR | 1 |
| Colombo, J | 1 |
| Zuccari, DA | 2 |
| Borin, TF | 1 |
| Arbab, AS | 1 |
| Gelaleti, GB | 1 |
| Ferreira, LC | 1 |
| Iskander, AS | 1 |
| Varma, NR | 1 |
| Shankar, A | 1 |
| Coimbra, VB | 1 |
| Fabri, VA | 1 |
| de Oliveira, JG | 1 |
| Mao, L | 3 |
| Dauchy, RT | 3 |
| Blask, DE | 3 |
| Dauchy, EM | 1 |
| Slakey, LM | 1 |
| Brimer, S | 1 |
| Yuan, L | 3 |
| Xiang, S | 3 |
| Hauch, A | 1 |
| Smith, K | 1 |
| Frasch, T | 2 |
| Belancio, VP | 1 |
| Wren, MA | 1 |
| Hill, SM | 3 |
| Lee, LM | 1 |
| Tan, P | 1 |
| Chen, WY | 1 |
| Summers, W | 1 |
| Reynolds, A | 1 |
| Wren-Dail, MA | 1 |
| Pointer, D | 1 |
| Ho, HY | 1 |
| Hsieh, MJ | 1 |
| Yang, WE | 1 |
| Chung, WH | 1 |
| Söderquist, F | 1 |
| Janson, ET | 1 |
| Rasmusson, AJ | 1 |
| Ali, A | 1 |
| Stridsberg, M | 1 |
| Cunningham, JL | 1 |
| Duplessis, T | 1 |
| Dauchy, E | 1 |
| Sauer, LA | 1 |
| Mazzoccoli, G | 1 |
| Sothern, RB | 1 |
| Parrella, P | 1 |
| Muscarella, LA | 1 |
| Fazio, VM | 1 |
| Giuliani, F | 1 |
| Polyakova, V | 1 |
| Kvetnoy, IM | 1 |
| Lissoni, P | 12 |
| Chilelli, M | 2 |
| Villa, S | 1 |
| Cerizza, L | 1 |
| Tancini, G | 10 |
| WURTMAN, RJ | 1 |
| AXELROD, J | 1 |
| Anisimov, VN | 1 |
| Barni, S | 9 |
| Fossati, V | 2 |
| Ardizzoia, A | 6 |
| Cazzaniga, M | 2 |
| Frigerio, F | 1 |
| Meregalli, S | 1 |
| Esposti, D | 3 |
| Aldeghi, R | 1 |
| Piperno, A | 1 |
| Pozzi, M | 1 |
| Ricci, G | 1 |
| Conti, A | 1 |
| Maestroni, GJ | 2 |
| Neri, B | 1 |
| Fiorelli, C | 1 |
| Moroni, F | 1 |
| Nicita, G | 1 |
| Paoletti, MC | 1 |
| Ponchietti, R | 1 |
| Raugei, A | 1 |
| Santoni, G | 1 |
| Trippitelli, A | 1 |
| Grechi, G | 1 |
| Paolorossi, F | 5 |
| Brivio, F | 2 |
| Zubelewicz, B | 1 |
| Chatikhine, V | 1 |
| Cos, S | 2 |
| Fernández, R | 1 |
| Güézmes, A | 1 |
| Sánchez-Barceló, EJ | 2 |
| Leman, ES | 1 |
| Sisken, BF | 1 |
| Zimmer, S | 1 |
| Anderson, KW | 1 |
| Garcia-Bolado, A | 1 |
| Raĭkhlin, NT | 1 |
| Kvetnoĭ, IM | 1 |
| Tisi, E | 2 |
| Rovelli, F | 2 |
| Rescaldani, R | 1 |
| Ballabio, D | 1 |
| Benenti, C | 1 |
| Angeli, M | 1 |
| Crispino, S | 3 |
| Archili, C | 2 |
| De Toma, D | 1 |
| Pipino, G | 1 |
| Falkson, G | 1 |
| Falkson, HC | 1 |
| Steyn, ME | 1 |
| Rapoport, BL | 1 |
| Meyer, BJ | 1 |
| Cattaneo, G | 1 |
| Lucini, V | 1 |
| Mariani, M | 1 |
| Esposti, G | 2 |
| Bastone, A | 1 |
| Sala, R | 1 |
| Mauri, R | 1 |
| Viviani, S | 1 |
| Bajetta, E | 1 |
| di Bella, L | 1 |
| Greisheimer, EM | 1 |
12 reviews available for melatonin and Metastase
| Article | Year |
|---|---|
Therapeutic Opportunities in Colorectal Cancer: Focus on Melatonin Antioncogenic Action.
Topics: Apoptosis; Autophagy; Cell Proliferation; Circadian Rhythm; Colorectal Neoplasms; Gastrointestinal T | 2019 |
New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence.
Topics: Adolescent; Animals; Bone Neoplasms; Child; Humans; Melatonin; Muscle Neoplasms; Neoplasm Invasivene | 2020 |
Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.
Topics: Apoptosis; Cell Proliferation; Drug-Related Side Effects and Adverse Reactions; Humans; Melatonin; N | 2021 |
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, | 2017 |
Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer.
Topics: Animals; Antineoplastic Agents; Humans; Melatonin; Neoplasm Metastasis; Neovascularization, Patholog | 2017 |
Therapeutic potential of melatonin for breast cancer radiation therapy patients.
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Estrogen Receptor alpha; Female; H | 2018 |
Mechanisms Underlying Tumor Suppressive Properties of Melatonin.
Topics: Aging; Animals; Anticarcinogenic Agents; Antioxidants; Carcinogenesis; Disease Models, Animal; Disea | 2018 |
5-methoxyindole metabolites of L-tryptophan: control of COX-2 expression, inflammation and tumorigenesis.
Topics: Carcinogenesis; Cyclooxygenase 2; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inflammat | 2014 |
Cancer metastasis: Mechanisms of inhibition by melatonin.
Topics: Animals; Humans; Melatonin; Neoplasm Metastasis | 2017 |
Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night.
Topics: Breast Neoplasms; Cell Proliferation; Circadian Rhythm; Diet; Female; Gene Expression Regulation, Ne | 2011 |
[Epiphysis (pineal gland) and tumorous growth].
Topics: Adjuvants, Immunologic; Animals; Carcinoma 256, Walker; Carcinoma, Ehrlich Tumor; Cell Transformatio | 1980 |
The pineal gland.
Topics: Animals; Biological Clocks; Cattle; Chemoreceptor Cells; Humans; Light; Mast Cells; Melatonin; Neopl | 1968 |
9 trials available for melatonin and Metastase
| Article | Year |
|---|---|
Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; | 2003 |
A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Hospice Care; Humans; Immunoth | 1995 |
Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Insulin-Like Growth Factor I; Melatonin; Middle Aged; | 1995 |
Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Melato | 1994 |
Is there a role for melatonin in the treatment of neoplastic cachexia?
Topics: Adult; Aged; Cachexia; Female; Humans; Male; Melatonin; Middle Aged; Neoplasm Metastasis; Palliative | 1996 |
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 1996 |
Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
Topics: 5-Methoxytryptamine; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Indoles; | 2000 |
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
Topics: Biopterins; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; | 1992 |
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance; Humans; Lung Neoplasms; Mel | 1992 |
32 other studies available for melatonin and Metastase
| Article | Year |
|---|---|
Effects of Melatonin and Doxorubicin on Primary Tumor And Metastasis in Breast Cancer Model.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; Melatonin | 2022 |
The metastatic spread of breast cancer accelerates during sleep.
Topics: Animals; Breast Neoplasms; Cell Count; Cell Proliferation; Disease Models, Animal; Female; Glucocort | 2022 |
The role of selected molecular factors in ovarian cancer metastasis.
Topics: Ascites; Carcinoma, Ovarian Epithelial; Cell Movement; Female; Gene Expression Regulation, Neoplasti | 2022 |
Extracellular Acidosis Promotes Metastatic Potency via Decrease of the
Topics: Acidosis; ARNTL Transcription Factors; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Surviv | 2020 |
Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma.
Topics: ADAMTS1 Protein; Animals; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Kidney Ne | 2020 |
Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE/AKT/β-catenin/SLUG axis.
Topics: Animals; beta Catenin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Epithelial Ce | 2020 |
Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Movement; Cell Survival; Down-Regulation; Humans; Male; | 2021 |
Synergistic potential of dual andrographolide and melatonin targeting of metastatic colon cancer cells: Using the Chou-Talalay combination index method.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neop | 2021 |
FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
Topics: Animals; Fibroblast Growth Factors; Humans; Melatonin; Mice; Neoplasm Metastasis; Receptor, Fibrobla | 2021 |
Melatonin decreases metastasis, primary tumor growth and angiogenesis in a mice model of breast cancer.
Topics: Angiogenesis Modulating Agents; Animals; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; | 2021 |
Melanin pigmentation and melanoma.
Topics: DNA Damage; Humans; Melanins; Melanocytes; Melanoma; Melatonin; Neoplasm Metastasis; Oxidants; Pigme | 2017 |
Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Disease Progression; Epith | 2018 |
Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cadherins | 2019 |
Melatonin effect on the ultrastructure of Ehrlich ascites tumor cells, lifetime and histopathology in Swiss mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Carcinoma, Ehrlich Tumor; Cell Proliferatio | 2013 |
Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Gene Expression; Humans; | 2014 |
Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression.
Topics: Amides; Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Melatonin; Mice; Mice, Nude; Ne | 2016 |
Melatonin suppression of aerobic glycolysis (Warburg effect), survival signalling and metastasis in human leiomyosarcoma.
Topics: Animals; Cell Survival; Female; Glycolysis; Humans; Leiomyosarcoma; Melatonin; Neoplasm Metastasis; | 2016 |
Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity.
Topics: Animals; Carcinoma, Renal Cell; DNA, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Express | 2016 |
Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Gene Express | 2016 |
Melatonin suppresses TPA-induced metastasis by downregulating matrix metalloproteinase-9 expression through JNK/SP-1 signaling in nasopharyngeal carcinoma.
Topics: Carcinoma; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expressi | 2016 |
Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gene Expression Regulation, Neoplasti | 2016 |
Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls.
Topics: Adult; Analysis of Variance; B-Lymphocyte Subsets; Body Mass Index; Carcinoma, Non-Small-Cell Lung; | 2012 |
DEMONSTRATION OF HYDROXYINDOLE-O-METHYL TRANSFERASE, MELATONIN, AND SEROTONIN IN A METASTATIC PARENCHYMATOUS PINEALOMA.
Topics: Carbon Isotopes; Chromatography; Histocytochemistry; Indoles; Melatonin; Neoplasm Metastasis; Pineal | 1964 |
Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Biopterins; Carcinoma, Hepatocellular; Eosinophils; Female; Humans; Injections, Subcuta | 1994 |
Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Basement Membrane; Breast Neoplasms; Cadherins; Cell | 1998 |
Studies of the interactions between melatonin and 2 Hz, 0.3 mT PEMF on the proliferation and invasion of human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Electromagnetic Fields; Female; Humans; Melatonin; Neoplasm Invasiv | 2001 |
Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19).
Topics: Animals; Coloring Agents; Dose-Response Relationship, Drug; Humans; Melanoma, Experimental; Melatoni | 2001 |
[Dynamics of changes in enterochromaffin cells during tumor growth].
Topics: Chromaffin System; Enterochromaffin Cells; Gastrointestinal Neoplasms; Humans; Hyperplasia; Leukemia | 1976 |
Plasma melatonin in patients with breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Melatonin; Menopause; Middle Aged; Neoplasm Met | 1990 |
A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Fol | 1990 |
Relation between lymphocyte subpopulations and pineal function in patients with early or metastatic cancer.
Topics: Adult; Aged; Female; Humans; Immunity, Cellular; Lymphocytes; Male; Melatonin; Middle Aged; Neoplasm | 1988 |
The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Growth Hormone; Humans; Ma | 1987 |